CareDx, Horizon Discovery Group Collaborate on Development of Cell-Free DNA Reference Standards
CareDx and the Horizon Discovery Group have entered into a strategic partnership to develop cell-free DNA reference standards, the two companies announced Wednesday.
Horizon Diagnostics, a division of Horizon, will conduct most of the active development of the standards, which will then be used to support CareDx’s solid organ transplant injury monitoring diagnostic tests, as well as being incorporated into CLIA laboratory testing. The standards mimic plasma cfDNA size and amount in transplant settings and are the first standards of their kind to be commercially available, the companies claim.
CareDx is located in Brisbane, Calif., while Horizon is based in the UK.
In the U.S., there are an estimated 300,000 solid organ transplant patients. — Jason Scott